The World Health Organization now recommends injectable lenacapavir as a twice-yearly option for HIV prevention, providing a highly effective alternative to daily oral pills. This long-acting injectable can improve adherence and access, especially for people facing challenges with daily medication, stigma, or healthcare access. Its use could significantly enhance HIV prevention efforts globally, particularly in high-risk populations.
